nodes	percent_of_prediction	percent_of_DWPC	metapath
Methsuximide—Hyperaemia—Dexamethasone—multiple sclerosis	0.0265	0.0332	CcSEcCtD
Methsuximide—Hyperaemia—Betamethasone—multiple sclerosis	0.0265	0.0332	CcSEcCtD
Methsuximide—Weight decreased—Fingolimod—multiple sclerosis	0.0178	0.0223	CcSEcCtD
Methsuximide—CACNA1I—NCAM1 interactions—PRNP—multiple sclerosis	0.0174	0.0867	CbGpPWpGaD
Methsuximide—Proteinuria—Mitoxantrone—multiple sclerosis	0.0133	0.0167	CcSEcCtD
Methsuximide—Protein urine present—Mitoxantrone—multiple sclerosis	0.0131	0.0164	CcSEcCtD
Methsuximide—Vision blurred—Fingolimod—multiple sclerosis	0.0129	0.0162	CcSEcCtD
Methsuximide—CACNA1G—NCAM1 interactions—PRNP—multiple sclerosis	0.0128	0.0639	CbGpPWpGaD
Methsuximide—CACNA1H—NCAM1 interactions—PRNP—multiple sclerosis	0.0124	0.0619	CbGpPWpGaD
Methsuximide—Leukopenia—Fingolimod—multiple sclerosis	0.0123	0.0154	CcSEcCtD
Methsuximide—Ataxia—Cladribine—multiple sclerosis	0.0122	0.0152	CcSEcCtD
Methsuximide—Eosinophilia—Cladribine—multiple sclerosis	0.0111	0.0138	CcSEcCtD
Methsuximide—Pancytopenia—Cladribine—multiple sclerosis	0.0106	0.0133	CcSEcCtD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—PRNP—multiple sclerosis	0.0102	0.0509	CbGpPWpGaD
Methsuximide—Stevens-Johnson syndrome—Cladribine—multiple sclerosis	0.00988	0.0124	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Fingolimod—multiple sclerosis	0.00968	0.0121	CcSEcCtD
Methsuximide—Hiccups—Prednisolone—multiple sclerosis	0.00961	0.012	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—CD24—multiple sclerosis	0.0089	0.0443	CbGpPWpGaD
Methsuximide—Hiccups—Triamcinolone—multiple sclerosis	0.00884	0.0111	CcSEcCtD
Methsuximide—Hiccups—Methylprednisolone—multiple sclerosis	0.00882	0.011	CcSEcCtD
Methsuximide—Pancytopenia—Azathioprine—multiple sclerosis	0.00863	0.0108	CcSEcCtD
Methsuximide—Erythema multiforme—Cladribine—multiple sclerosis	0.00846	0.0106	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Azathioprine—multiple sclerosis	0.00803	0.0101	CcSEcCtD
Methsuximide—Hiccups—Dexamethasone—multiple sclerosis	0.00802	0.01	CcSEcCtD
Methsuximide—Hiccups—Betamethasone—multiple sclerosis	0.00802	0.01	CcSEcCtD
Methsuximide—Diarrhoea—Fingolimod—multiple sclerosis	0.00767	0.0096	CcSEcCtD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—PRNP—multiple sclerosis	0.00754	0.0376	CbGpPWpGaD
Methsuximide—Dizziness—Fingolimod—multiple sclerosis	0.00741	0.00928	CcSEcCtD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—PRNP—multiple sclerosis	0.00731	0.0364	CbGpPWpGaD
Methsuximide—Headache—Fingolimod—multiple sclerosis	0.00702	0.00879	CcSEcCtD
Methsuximide—Hiccups—Prednisone—multiple sclerosis	0.00698	0.00874	CcSEcCtD
Methsuximide—Pancytopenia—Mitoxantrone—multiple sclerosis	0.00698	0.00873	CcSEcCtD
Methsuximide—Erythema multiforme—Azathioprine—multiple sclerosis	0.00688	0.00861	CcSEcCtD
Methsuximide—Weight decreased—Mitoxantrone—multiple sclerosis	0.00665	0.00832	CcSEcCtD
Methsuximide—Proteinuria—Methotrexate—multiple sclerosis	0.00664	0.00831	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—CD24—multiple sclerosis	0.00656	0.0326	CbGpPWpGaD
Methsuximide—Drowsiness—Mitoxantrone—multiple sclerosis	0.00655	0.0082	CcSEcCtD
Methsuximide—Protein urine present—Methotrexate—multiple sclerosis	0.00655	0.00819	CcSEcCtD
Methsuximide—Confusional state—Cladribine—multiple sclerosis	0.00641	0.00802	CcSEcCtD
Methsuximide—CACNA1H—Axon guidance—CD24—multiple sclerosis	0.00635	0.0316	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—CD24—multiple sclerosis	0.00635	0.0316	CbGpPWpGaD
Methsuximide—Psychotic disorder—Methylprednisolone—multiple sclerosis	0.00625	0.00782	CcSEcCtD
Methsuximide—Haematuria—Mitoxantrone—multiple sclerosis	0.00625	0.00782	CcSEcCtD
Methsuximide—Irritability—Methylprednisolone—multiple sclerosis	0.00611	0.00764	CcSEcCtD
Methsuximide—Anorexia—Cladribine—multiple sclerosis	0.00606	0.00758	CcSEcCtD
Methsuximide—Insomnia—Cladribine—multiple sclerosis	0.00575	0.00719	CcSEcCtD
Methsuximide—Psychotic disorder—Dexamethasone—multiple sclerosis	0.00568	0.00711	CcSEcCtD
Methsuximide—Psychotic disorder—Betamethasone—multiple sclerosis	0.00568	0.00711	CcSEcCtD
Methsuximide—Leukopenia—Azathioprine—multiple sclerosis	0.00567	0.00709	CcSEcCtD
Methsuximide—Somnolence—Cladribine—multiple sclerosis	0.00565	0.00707	CcSEcCtD
Methsuximide—Irritability—Dexamethasone—multiple sclerosis	0.00555	0.00695	CcSEcCtD
Methsuximide—Irritability—Betamethasone—multiple sclerosis	0.00555	0.00695	CcSEcCtD
Methsuximide—Decreased appetite—Cladribine—multiple sclerosis	0.00553	0.00691	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.00549	0.00687	CcSEcCtD
Methsuximide—Constipation—Cladribine—multiple sclerosis	0.00544	0.0068	CcSEcCtD
Methsuximide—Feeling abnormal—Cladribine—multiple sclerosis	0.00524	0.00655	CcSEcCtD
Methsuximide—Gastrointestinal pain—Cladribine—multiple sclerosis	0.0052	0.0065	CcSEcCtD
Methsuximide—Urticaria—Cladribine—multiple sclerosis	0.00505	0.00632	CcSEcCtD
Methsuximide—Abdominal pain—Cladribine—multiple sclerosis	0.00502	0.00629	CcSEcCtD
Methsuximide—Psychotic disorder—Prednisone—multiple sclerosis	0.00495	0.00619	CcSEcCtD
Methsuximide—Irritability—Prednisone—multiple sclerosis	0.00484	0.00605	CcSEcCtD
Methsuximide—Vision blurred—Mitoxantrone—multiple sclerosis	0.00482	0.00604	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—CD24—multiple sclerosis	0.00468	0.0233	CbGpPWpGaD
Methsuximide—Leukopenia—Mitoxantrone—multiple sclerosis	0.00458	0.00573	CcSEcCtD
Methsuximide—Weight decreased—Dexamethasone—multiple sclerosis	0.00455	0.00569	CcSEcCtD
Methsuximide—Weight decreased—Betamethasone—multiple sclerosis	0.00455	0.00569	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—CD24—multiple sclerosis	0.00453	0.0226	CbGpPWpGaD
Methsuximide—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.00446	0.00558	CcSEcCtD
Methsuximide—Diarrhoea—Cladribine—multiple sclerosis	0.00435	0.00544	CcSEcCtD
Methsuximide—Feeling abnormal—Azathioprine—multiple sclerosis	0.00426	0.00533	CcSEcCtD
Methsuximide—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.00423	0.00529	CcSEcCtD
Methsuximide—Confusional state—Mitoxantrone—multiple sclerosis	0.00421	0.00527	CcSEcCtD
Methsuximide—Dizziness—Cladribine—multiple sclerosis	0.0042	0.00526	CcSEcCtD
Methsuximide—Abdominal pain—Azathioprine—multiple sclerosis	0.00409	0.00511	CcSEcCtD
Methsuximide—Irritability—Methotrexate—multiple sclerosis	0.00404	0.00506	CcSEcCtD
Methsuximide—Vomiting—Cladribine—multiple sclerosis	0.00404	0.00506	CcSEcCtD
Methsuximide—Rash—Cladribine—multiple sclerosis	0.00401	0.00502	CcSEcCtD
Methsuximide—Dermatitis—Cladribine—multiple sclerosis	0.004	0.00501	CcSEcCtD
Methsuximide—Anorexia—Mitoxantrone—multiple sclerosis	0.00398	0.00498	CcSEcCtD
Methsuximide—Ataxia—Methotrexate—multiple sclerosis	0.00398	0.00498	CcSEcCtD
Methsuximide—Headache—Cladribine—multiple sclerosis	0.00398	0.00498	CcSEcCtD
Methsuximide—Weight decreased—Prednisone—multiple sclerosis	0.00396	0.00496	CcSEcCtD
Methsuximide—Vision blurred—Prednisolone—multiple sclerosis	0.00396	0.00495	CcSEcCtD
Methsuximide—Nausea—Cladribine—multiple sclerosis	0.00378	0.00472	CcSEcCtD
Methsuximide—Somnolence—Mitoxantrone—multiple sclerosis	0.00371	0.00465	CcSEcCtD
Methsuximide—Decreased appetite—Mitoxantrone—multiple sclerosis	0.00363	0.00454	CcSEcCtD
Methsuximide—Eosinophilia—Methotrexate—multiple sclerosis	0.00362	0.00454	CcSEcCtD
Methsuximide—Constipation—Mitoxantrone—multiple sclerosis	0.00357	0.00447	CcSEcCtD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—TYK2—multiple sclerosis	0.00356	0.0177	CbGpPWpGaD
Methsuximide—Diarrhoea—Azathioprine—multiple sclerosis	0.00354	0.00443	CcSEcCtD
Methsuximide—Pancytopenia—Methotrexate—multiple sclerosis	0.00348	0.00435	CcSEcCtD
Methsuximide—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.00344	0.00431	CcSEcCtD
Methsuximide—Dizziness—Azathioprine—multiple sclerosis	0.00342	0.00428	CcSEcCtD
Methsuximide—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.00342	0.00428	CcSEcCtD
Methsuximide—Urticaria—Mitoxantrone—multiple sclerosis	0.00332	0.00415	CcSEcCtD
Methsuximide—Abdominal pain—Mitoxantrone—multiple sclerosis	0.0033	0.00413	CcSEcCtD
Methsuximide—Vomiting—Azathioprine—multiple sclerosis	0.00329	0.00411	CcSEcCtD
Methsuximide—Drowsiness—Methotrexate—multiple sclerosis	0.00326	0.00408	CcSEcCtD
Methsuximide—Rash—Azathioprine—multiple sclerosis	0.00326	0.00408	CcSEcCtD
Methsuximide—Dermatitis—Azathioprine—multiple sclerosis	0.00326	0.00407	CcSEcCtD
Methsuximide—Headache—Azathioprine—multiple sclerosis	0.00324	0.00405	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	0.00324	0.00405	CcSEcCtD
Methsuximide—Confusional state—Methylprednisolone—multiple sclerosis	0.00317	0.00397	CcSEcCtD
Methsuximide—Haematuria—Methotrexate—multiple sclerosis	0.00311	0.00389	CcSEcCtD
Methsuximide—Insomnia—Prednisolone—multiple sclerosis	0.0031	0.00388	CcSEcCtD
Methsuximide—Nausea—Azathioprine—multiple sclerosis	0.00307	0.00384	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—PRNP—multiple sclerosis	0.00293	0.0146	CbGpPWpGaD
Methsuximide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.00291	0.0145	CbGpPWpGaD
Methsuximide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.00291	0.0145	CbGpPWpGaD
Methsuximide—Vision blurred—Prednisone—multiple sclerosis	0.00288	0.0036	CcSEcCtD
Methsuximide—CYP2C19—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.00287	0.0143	CbGpPWpGaD
Methsuximide—CYP2C19—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.00287	0.0143	CbGpPWpGaD
Methsuximide—Diarrhoea—Mitoxantrone—multiple sclerosis	0.00286	0.00358	CcSEcCtD
Methsuximide—Insomnia—Triamcinolone—multiple sclerosis	0.00285	0.00357	CcSEcCtD
Methsuximide—Insomnia—Methylprednisolone—multiple sclerosis	0.00284	0.00356	CcSEcCtD
Methsuximide—Feeling abnormal—Prednisolone—multiple sclerosis	0.00282	0.00353	CcSEcCtD
Methsuximide—Erythema multiforme—Methotrexate—multiple sclerosis	0.00277	0.00347	CcSEcCtD
Methsuximide—Anorexia—Betamethasone—multiple sclerosis	0.00273	0.00341	CcSEcCtD
Methsuximide—Anorexia—Dexamethasone—multiple sclerosis	0.00273	0.00341	CcSEcCtD
Methsuximide—Urticaria—Prednisolone—multiple sclerosis	0.00272	0.00341	CcSEcCtD
Methsuximide—Vomiting—Mitoxantrone—multiple sclerosis	0.00266	0.00332	CcSEcCtD
Methsuximide—Rash—Mitoxantrone—multiple sclerosis	0.00263	0.0033	CcSEcCtD
Methsuximide—Dermatitis—Mitoxantrone—multiple sclerosis	0.00263	0.00329	CcSEcCtD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—TYK2—multiple sclerosis	0.00263	0.0131	CbGpPWpGaD
Methsuximide—Headache—Mitoxantrone—multiple sclerosis	0.00262	0.00328	CcSEcCtD
Methsuximide—Feeling abnormal—Triamcinolone—multiple sclerosis	0.0026	0.00325	CcSEcCtD
Methsuximide—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.00259	0.00324	CcSEcCtD
Methsuximide—Insomnia—Dexamethasone—multiple sclerosis	0.00259	0.00324	CcSEcCtD
Methsuximide—Insomnia—Betamethasone—multiple sclerosis	0.00259	0.00324	CcSEcCtD
Methsuximide—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.00257	0.00322	CcSEcCtD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—TLR4—multiple sclerosis	0.00256	0.0128	CbGpPWpGaD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—TYK2—multiple sclerosis	0.00254	0.0127	CbGpPWpGaD
Methsuximide—Urticaria—Triamcinolone—multiple sclerosis	0.0025	0.00313	CcSEcCtD
Methsuximide—Urticaria—Methylprednisolone—multiple sclerosis	0.0025	0.00313	CcSEcCtD
Methsuximide—Abdominal pain—Methylprednisolone—multiple sclerosis	0.00249	0.00311	CcSEcCtD
Methsuximide—Decreased appetite—Dexamethasone—multiple sclerosis	0.00249	0.00311	CcSEcCtD
Methsuximide—Decreased appetite—Betamethasone—multiple sclerosis	0.00249	0.00311	CcSEcCtD
Methsuximide—Nausea—Mitoxantrone—multiple sclerosis	0.00248	0.00311	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.00247	0.00309	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.00247	0.00309	CcSEcCtD
Methsuximide—Vision blurred—Methotrexate—multiple sclerosis	0.0024	0.00301	CcSEcCtD
Methsuximide—Anorexia—Prednisone—multiple sclerosis	0.00237	0.00297	CcSEcCtD
Methsuximide—CYP2C19—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.00236	0.0118	CbGpPWpGaD
Methsuximide—CYP2C19—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.00236	0.0118	CbGpPWpGaD
Methsuximide—Feeling abnormal—Dexamethasone—multiple sclerosis	0.00236	0.00295	CcSEcCtD
Methsuximide—Feeling abnormal—Betamethasone—multiple sclerosis	0.00236	0.00295	CcSEcCtD
Methsuximide—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.00234	0.00293	CcSEcCtD
Methsuximide—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.00234	0.00293	CcSEcCtD
Methsuximide—Leukopenia—Methotrexate—multiple sclerosis	0.00228	0.00286	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—PTPRC—multiple sclerosis	0.00228	0.0114	CbGpPWpGaD
Methsuximide—Urticaria—Dexamethasone—multiple sclerosis	0.00227	0.00284	CcSEcCtD
Methsuximide—Urticaria—Betamethasone—multiple sclerosis	0.00227	0.00284	CcSEcCtD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—MAPK1—multiple sclerosis	0.00227	0.0113	CbGpPWpGaD
Methsuximide—Dizziness—Prednisolone—multiple sclerosis	0.00227	0.00284	CcSEcCtD
Methsuximide—Abdominal pain—Dexamethasone—multiple sclerosis	0.00226	0.00283	CcSEcCtD
Methsuximide—Abdominal pain—Betamethasone—multiple sclerosis	0.00226	0.00283	CcSEcCtD
Methsuximide—Insomnia—Prednisone—multiple sclerosis	0.00225	0.00282	CcSEcCtD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—POMC—multiple sclerosis	0.00225	0.0112	CbGpPWpGaD
Methsuximide—Decreased appetite—Prednisone—multiple sclerosis	0.00217	0.00271	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—PRNP—multiple sclerosis	0.00216	0.0108	CbGpPWpGaD
Methsuximide—Rash—Prednisolone—multiple sclerosis	0.00216	0.0027	CcSEcCtD
Methsuximide—Dermatitis—Prednisolone—multiple sclerosis	0.00216	0.0027	CcSEcCtD
Methsuximide—Diarrhoea—Methylprednisolone—multiple sclerosis	0.00215	0.00269	CcSEcCtD
Methsuximide—Headache—Prednisolone—multiple sclerosis	0.00215	0.00269	CcSEcCtD
Methsuximide—Constipation—Prednisone—multiple sclerosis	0.00213	0.00267	CcSEcCtD
Methsuximide—Confusional state—Methotrexate—multiple sclerosis	0.0021	0.00263	CcSEcCtD
Methsuximide—CACNA1H—Axon guidance—PRNP—multiple sclerosis	0.0021	0.0104	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—PRNP—multiple sclerosis	0.00209	0.0104	CbGpPWpGaD
Methsuximide—Dizziness—Triamcinolone—multiple sclerosis	0.00208	0.00261	CcSEcCtD
Methsuximide—Dizziness—Methylprednisolone—multiple sclerosis	0.00208	0.0026	CcSEcCtD
Methsuximide—Feeling abnormal—Prednisone—multiple sclerosis	0.00205	0.00257	CcSEcCtD
Methsuximide—Gastrointestinal pain—Prednisone—multiple sclerosis	0.00204	0.00255	CcSEcCtD
Methsuximide—Nausea—Prednisolone—multiple sclerosis	0.00204	0.00255	CcSEcCtD
Methsuximide—Vomiting—Triamcinolone—multiple sclerosis	0.002	0.00251	CcSEcCtD
Methsuximide—Vomiting—Methylprednisolone—multiple sclerosis	0.002	0.0025	CcSEcCtD
Methsuximide—Rash—Triamcinolone—multiple sclerosis	0.00199	0.00249	CcSEcCtD
Methsuximide—Dermatitis—Triamcinolone—multiple sclerosis	0.00199	0.00248	CcSEcCtD
Methsuximide—Anorexia—Methotrexate—multiple sclerosis	0.00198	0.00248	CcSEcCtD
Methsuximide—Rash—Methylprednisolone—multiple sclerosis	0.00198	0.00248	CcSEcCtD
Methsuximide—Dermatitis—Methylprednisolone—multiple sclerosis	0.00198	0.00248	CcSEcCtD
Methsuximide—Urticaria—Prednisone—multiple sclerosis	0.00198	0.00248	CcSEcCtD
Methsuximide—Headache—Triamcinolone—multiple sclerosis	0.00197	0.00247	CcSEcCtD
Methsuximide—Headache—Methylprednisolone—multiple sclerosis	0.00197	0.00247	CcSEcCtD
Methsuximide—Abdominal pain—Prednisone—multiple sclerosis	0.00197	0.00246	CcSEcCtD
Methsuximide—Diarrhoea—Betamethasone—multiple sclerosis	0.00196	0.00245	CcSEcCtD
Methsuximide—Diarrhoea—Dexamethasone—multiple sclerosis	0.00196	0.00245	CcSEcCtD
Methsuximide—Dizziness—Betamethasone—multiple sclerosis	0.00189	0.00237	CcSEcCtD
Methsuximide—Dizziness—Dexamethasone—multiple sclerosis	0.00189	0.00237	CcSEcCtD
Methsuximide—Insomnia—Methotrexate—multiple sclerosis	0.00188	0.00236	CcSEcCtD
Methsuximide—Nausea—Triamcinolone—multiple sclerosis	0.00187	0.00234	CcSEcCtD
Methsuximide—Nausea—Methylprednisolone—multiple sclerosis	0.00187	0.00234	CcSEcCtD
Methsuximide—Somnolence—Methotrexate—multiple sclerosis	0.00185	0.00232	CcSEcCtD
Methsuximide—Vomiting—Dexamethasone—multiple sclerosis	0.00182	0.00228	CcSEcCtD
Methsuximide—Vomiting—Betamethasone—multiple sclerosis	0.00182	0.00228	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—multiple sclerosis	0.00182	0.00904	CbGpPWpGaD
Methsuximide—Decreased appetite—Methotrexate—multiple sclerosis	0.00181	0.00226	CcSEcCtD
Methsuximide—Rash—Betamethasone—multiple sclerosis	0.0018	0.00226	CcSEcCtD
Methsuximide—Rash—Dexamethasone—multiple sclerosis	0.0018	0.00226	CcSEcCtD
Methsuximide—Dermatitis—Dexamethasone—multiple sclerosis	0.0018	0.00225	CcSEcCtD
Methsuximide—Dermatitis—Betamethasone—multiple sclerosis	0.0018	0.00225	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.0018	0.00225	CcSEcCtD
Methsuximide—Headache—Dexamethasone—multiple sclerosis	0.00179	0.00224	CcSEcCtD
Methsuximide—Headache—Betamethasone—multiple sclerosis	0.00179	0.00224	CcSEcCtD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—IL6—multiple sclerosis	0.00174	0.00867	CbGpPWpGaD
Methsuximide—Feeling abnormal—Methotrexate—multiple sclerosis	0.00172	0.00215	CcSEcCtD
Methsuximide—Diarrhoea—Prednisone—multiple sclerosis	0.0017	0.00213	CcSEcCtD
Methsuximide—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.0017	0.00213	CcSEcCtD
Methsuximide—Nausea—Dexamethasone—multiple sclerosis	0.0017	0.00213	CcSEcCtD
Methsuximide—Nausea—Betamethasone—multiple sclerosis	0.0017	0.00213	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—PTPRC—multiple sclerosis	0.00168	0.00838	CbGpPWpGaD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—MAPK1—multiple sclerosis	0.00167	0.00832	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—IL2—multiple sclerosis	0.00166	0.00827	CbGpPWpGaD
Methsuximide—Urticaria—Methotrexate—multiple sclerosis	0.00165	0.00207	CcSEcCtD
Methsuximide—Dizziness—Prednisone—multiple sclerosis	0.00165	0.00206	CcSEcCtD
Methsuximide—Abdominal pain—Methotrexate—multiple sclerosis	0.00165	0.00206	CcSEcCtD
Methsuximide—CACNA1H—Axon guidance—PTPRC—multiple sclerosis	0.00163	0.00811	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—PTPRC—multiple sclerosis	0.00163	0.00811	CbGpPWpGaD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—MAPK1—multiple sclerosis	0.00162	0.00806	CbGpPWpGaD
Methsuximide—Vomiting—Prednisone—multiple sclerosis	0.00158	0.00198	CcSEcCtD
Methsuximide—Rash—Prednisone—multiple sclerosis	0.00157	0.00197	CcSEcCtD
Methsuximide—Dermatitis—Prednisone—multiple sclerosis	0.00157	0.00196	CcSEcCtD
Methsuximide—Headache—Prednisone—multiple sclerosis	0.00156	0.00195	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—PRNP—multiple sclerosis	0.00154	0.00769	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—multiple sclerosis	0.0015	0.00747	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—PRNP—multiple sclerosis	0.0015	0.00744	CbGpPWpGaD
Methsuximide—Nausea—Prednisone—multiple sclerosis	0.00148	0.00185	CcSEcCtD
Methsuximide—Diarrhoea—Methotrexate—multiple sclerosis	0.00142	0.00178	CcSEcCtD
Methsuximide—Dizziness—Methotrexate—multiple sclerosis	0.00138	0.00172	CcSEcCtD
Methsuximide—CYP2C19—Melatonin metabolism and effects—APOE—multiple sclerosis	0.00136	0.00679	CbGpPWpGaD
Methsuximide—Vomiting—Methotrexate—multiple sclerosis	0.00132	0.00166	CcSEcCtD
Methsuximide—Rash—Methotrexate—multiple sclerosis	0.00131	0.00164	CcSEcCtD
Methsuximide—Dermatitis—Methotrexate—multiple sclerosis	0.00131	0.00164	CcSEcCtD
Methsuximide—Headache—Methotrexate—multiple sclerosis	0.0013	0.00163	CcSEcCtD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—TGFB1—multiple sclerosis	0.0013	0.00645	CbGpPWpGaD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—IL6—multiple sclerosis	0.00128	0.00639	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—MAPK1—multiple sclerosis	0.00127	0.00633	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—CYP24A1—multiple sclerosis	0.00125	0.00624	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—CYP27B1—multiple sclerosis	0.00125	0.00624	CbGpPWpGaD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—IL6—multiple sclerosis	0.00124	0.00619	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00124	0.00616	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00124	0.00616	CbGpPWpGaD
Methsuximide—Nausea—Methotrexate—multiple sclerosis	0.00124	0.00155	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—PTPRC—multiple sclerosis	0.0012	0.00598	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—PTPRC—multiple sclerosis	0.00116	0.00579	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—TYK2—multiple sclerosis	0.00102	0.00508	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—MMP9—multiple sclerosis	0.000804	0.004	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—TYK2—multiple sclerosis	0.000753	0.00375	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—TYK2—multiple sclerosis	0.000729	0.00363	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—TYK2—multiple sclerosis	0.000729	0.00363	CbGpPWpGaD
Methsuximide—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000655	0.00326	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—MAPK1—multiple sclerosis	0.00065	0.00324	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—MMP9—multiple sclerosis	0.000593	0.00295	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—MMP9—multiple sclerosis	0.000574	0.00286	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MMP9—multiple sclerosis	0.000574	0.00286	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—TYK2—multiple sclerosis	0.000537	0.00267	CbGpPWpGaD
Methsuximide—CYP2C19—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000531	0.00264	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—TYK2—multiple sclerosis	0.00052	0.00259	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—STAT3—multiple sclerosis	0.00051	0.00254	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—IL6—multiple sclerosis	0.000499	0.00249	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000482	0.0024	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000482	0.0024	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—MAPK1—multiple sclerosis	0.000479	0.00239	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—TGFB1—multiple sclerosis	0.000473	0.00235	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—MAPK1—multiple sclerosis	0.000464	0.00231	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MAPK1—multiple sclerosis	0.000464	0.00231	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—TNF—multiple sclerosis	0.000442	0.0022	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MMP9—multiple sclerosis	0.000423	0.00211	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MMP9—multiple sclerosis	0.00041	0.00204	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—STAT3—multiple sclerosis	0.000376	0.00187	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—IL6—multiple sclerosis	0.000368	0.00183	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—STAT3—multiple sclerosis	0.000364	0.00181	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—IL6—multiple sclerosis	0.000357	0.00178	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—IL6—multiple sclerosis	0.000356	0.00177	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—TGFB1—multiple sclerosis	0.000349	0.00174	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MAPK1—multiple sclerosis	0.000342	0.0017	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—TGFB1—multiple sclerosis	0.000338	0.00168	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MAPK1—multiple sclerosis	0.000331	0.00165	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—TNF—multiple sclerosis	0.000326	0.00162	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—TNF—multiple sclerosis	0.000315	0.00157	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SRM—multiple sclerosis	0.000304	0.00152	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—POMC—multiple sclerosis	0.000282	0.0014	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—IL6—multiple sclerosis	0.000263	0.00131	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—IL6—multiple sclerosis	0.000254	0.00127	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	0.000215	0.00107	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	0.000215	0.00107	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.00021	0.00104	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GPC5—multiple sclerosis	0.000196	0.000977	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—RRM1—multiple sclerosis	0.000163	0.000809	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	0.000126	0.000628	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	0.000108	0.000539	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	9.88e-05	0.000492	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—BCHE—multiple sclerosis	9.34e-05	0.000465	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—APOE—multiple sclerosis	5.62e-05	0.00028	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—POMC—multiple sclerosis	4.83e-05	0.00024	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ALB—multiple sclerosis	4.4e-05	0.000219	CbGpPWpGaD
